Full article: Comparative effectiveness and safety of inhaled corticosteroid plus long-acting
β2-agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis …

… Single-inhaler triple therapy showed a greater improvement in lung function, asthma control,
and health status and was noninferior to open-inhaler triple therapy for Asthma Quality of …

… However, there is a limitation in those patients with all chronic airway diseases such as
COPD, asthma, bronchiectasis, and tuberculosis-destroyed lung were targeted, and the …

… may also contribute to the effects observed in asthma and COPD. … to treat asthma, there
is increasing documentation that long-acting muscarinic … Novel bronchodilators in asthma …

… asthma or COPD beyond the patient's usual day-to-day variance?” [14]. For bronchodilator
… withheld short-acting bronchodilators for ≥6 h and long-acting bronchodilators for 12–24 h, …

… Roflumilast is a novel therapeutic drug for chronic obstructive pulmonary disease (COPD). …
inflammation complicated by asthma and COPD [8]. In terms of treating severe to profound …

… pre-bronchodilator FEV 1 % predicted) were taken from the most recent values before the
index date. Variables recorded at baseline included asthma diagnosis, COPD Assessment …

… Most of the novel therapeutic agents result from the … ICS withdrawal in COPD patients with
an asthmatic component is related … Long-acting bronchodilators are the central part of COPD …

… Long-acting bronchodilators are the cornerstone in the pharmacologic treatment of symptomatic
COPD … ratio < 0.7, and patients with current asthma are excluded from the CLUE registry. …

… investigation in the field of novel drug development for COPD therapy (Table 27.2). … asthma
suffers and long-acting anticholinergic drug tiotropium are useful in low to moderate asthma …